+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients



Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients



Aids Research and Human Retroviruses 15(16): 1413-1417



This open-label, multicenter trial evaluated the efficacy and safety of a new oral solution formulation of itraconazole in HIV+/AIDS patients with fluconazole-refractory oropharyngeal candidiasis. Seventy-four HIV+/AIDS patients with mycologically confirmed oropharyngeal candidiasis who failed fluconazole therapy (200 mg/day) were treated with 100 mg of itraconazole oral solution administered twice daily (200 mg/day) for 14 days. Patients who demonstrated an incomplete response to treatment were treated for an additional 14 days (28 days total). Clinical responders were eligible for participation in a separate 6-month maintenance protocol. If they declined further treatment, responders were monitored for 6 weeks posttreatment. The primary efficacy parameter was clinical response (i.e., no lesions or symptoms) at end of treatment. Fungal cultures were performed at baseline and at the end of treatment. Among the 74 patients who had mycologically confirmed, fluconazole-unresponsive, oropharyngeal candidiasis at baseline, 41 (55%) achieved a clinical response by day 28. The median time to response was 7 days (range, 7 to 28 days). Candida albicans was the most common pathogen isolated, either alone (62%) or in combination with another Candida species (31%). All 22 patients who entered the optional, off-therapy, 6-week follow-up phase relapsed; mean time to relapse was 13 days. Itraconazole oral solution was well-tolerated; adverse events were predominantly gastrointestinal disturbances. This trial demonstrates that itraconazole oral solution is a useful therapy in the treatment of HIV-infected patients with fluconazole-refractory oropharyngeal candidiasis.

(PDF emailed within 0-6 h: $19.90)

Accession: 011591848

Download citation: RISBibTeXText

PMID: 10555103

DOI: 10.1089/088922299309919


Related references

A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clinical Infectious Diseases 26(6): 1368-1373, 1998

A Double-Blind Comparison of Itraconazole Oral Solution and Fluconazole Capsules for the Treatment of Oropharyngeal Candidiasis in Patients with Aids. Clinical Infectious Diseases 26(6): 1368-1373, 1998

Itraconazole oral solution versus fluconazole treatment of oropharyngeal candidiasis. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 35(0): 244, 1995

Itraconazole solution for fluconazole-refractory oropharyngeal candidiasis in AIDS Correlation of clinical response with in vitro susceptibility. TENTH INTERNATIONAL CONFERENCE ON AIDS, INTERNATIONAL CONFERENCE ON STD Tenth International Conference on AIDS and the International Conference on STD, Vol 2; The global challenge of AIDS: Together for the future : 2) 23, 1994

Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. Aids 10(12): 1369-1376, 1996

Efficacy of alcohol-based and alcohol-free melaleuca oral solution for the treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS. HIV Clinical Trials 3(5): 379-385, 2002

Efficacy of Alcohol-Based and Alcohol-Free Melaleuca Oral Solution for the Treatment of Fluconazole-Refractory Oropharyngeal Candidiasis in Patients with Aids. Hiv Clinical Trials 3(5): 379-385, 2002

Comparison of itraconazole oral solution and fluconazole capsules in the treatment of oral and esophageal candidiasis in hiv infected patients preliminary results. Istituto Superiore Di Sanita Vii International Conference on Aids: Science Challenging Aids; Florence, Italy, June 16-21, 464p (Vol 1); 460p (Vol 2) Istituto Superiore Di Sanita: Rome, Italy Paper : 232, 1991

Evaluation of efficacy and safety of itraconazole oral solution for the treatment of oropharyngeal candidiasis in aids patients. Brazilian Journal of Infectious Diseases 5(2): 60-66, 2001

Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients. Clinical Therapeutics 19(3): 471-480, 1997

Oral amphotericin B inefficacy in the treatment of fluconazole++ resistant oropharyngeal candidiasis in HIV-positive patients. Revista Clinica Espanola 196(12): 878-879, 1996

Efficacy of melaleuca oral solution for the treatment of fluconazole refractory oral candidiasis in AIDS patients. Aids 12(9): 1033-1037, 1998

Randomized study of fluconazole oral solution versus amphotericin B oral solution in oropharyngeal candidiasis in elderly patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 38: 490, 1998

Fluconazole and itraconazole vs amphotericin B: in vitro comparative evaluation of the minimal inhibitory concentration (MIC) against isolated yeasts from HIV positive patients with oropharyngeal candidiasis. Igiene Moderna 111(4): 417-429, 1999

Itraconazole oral solution compared with fluconazole for treatment of esophageal candidiasis. ELEVENTH INTERNATIONAL CONFERENCE ON AIDS [Author] Eleventh International Conference on AIDS, Vol One One world: One hope : 17, 1996